Ansarin, 78 patient bromhexine early treatment RCT: 91% lower mortality [p=0.05], 89% lower ventilation [p=0.01], and 82% lower ICU admission [p=0.01] https://c19p.org/ansarin
copied to clipboard
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
et al., Bioimpacts, doi:10.34172/bi.2020.27
RCT with 39 bromhexine and 39 control patients showing lower mortality, intubation, and ICU admission with treatment. The treatment group received bromhexine hydrochloride 8 mg three times a day for two weeks. All patients received SOC including HCQ.Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
|
risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 39 (0.0%), control 5 of 39 (12.8%), NNT 7.8, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of mechanical ventilation, 88.9% lower, RR 0.11, p = 0.01, treatment 1 of 39 (2.6%), control 9 of 39 (23.1%), NNT 4.9.
|
|
risk of ICU admission, 81.8% lower, RR 0.18, p = 0.01, treatment 2 of 39 (5.1%), control 11 of 39 (28.2%), NNT 4.3.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ansarin et al., 7/19/2020, Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 11 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.